Zinzino group revenue increased with a total of 32 %, compared with the previous year.
The revenue in February for Zinzino‘s sales markets increased by 32 % and amounted to SEK 281.1 (212.7) million. Faun Pharma’s external sales increased and amounted to SEK 5.2 (4.2) million. Overall, the Group increased revenues by 32 % to SEK 286.3 (216.9) million compared with the previous year.
Accumulated revenue for January – February 2026 increased by 26 % to SEK 568.6 (450.8) million.
Revenues were distributed as follows:
Regions, MSEK
26-Feb
25-Feb
Change
YTD 2026
YTD 2025
Change
The Nordics
22.5
24.8
-9%
50.1
50.5
-1%
Central Europe
81.8
57.4
43%
171.0
126.8
35%
East Europe
26.2
29.0
-10%
55.9
63.2
-12%
South & West Europe
50.2
37.8
33%
97.2
82.0
19%
The Baltics
8.5
8.8
-3%
18.9
19.3
-2%
North America
67.5
32.5
108%
109.9
53.8
104%
South America
3.6
1.2
200%
7.5
2.1
257%
Asia-Pacific
18.6
19.7
-6%
41.7
41.2
1%
Africa
2.2
1.5
47%
4.1
3.0
37%
Zinzino
281.1
212.7
32%
556.3
441.9
26%
Faun Pharma
5.2
4.2
24%
12.3
8.9
38%
Zinzino Group
286.3
216.9
32%
568.6
450.8
26%
Countries in regions:
The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
Central Europe: Austria, Germany, Switzerland
East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
The Baltics: Estonia, Latvia, Lithuania
North America: Canada, USA, Mexico
South America: Peru, Colombia
Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines, South Korea
Africa: South Africa
About Zinzino
Zinzino AB (publ) (ZZ-B.ST) is a global direct-sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market.
Zinzino’s scientifically proven